Search Results

You are looking at 101 - 110 of 135 items for :

Clear All
Full access

Jonathan W. Riess, Seema Nagpal, Joel W. Neal and Heather A. Wakelee

gyrus consistent with leptomeningeal disease (arrow). platelet inhibitors (ticlopidine, cilostazol). Crizotinib, an oral ALK and MET small molecule tyrosine kinase inhibitor (TKI), was recently given accelerated approval by the FDA for patients

Full access

Andrew W. Hahn, Smith Giri, Dilan Patel, Heather Sluder, Ari Vanderwalde and Mike G. Martin

not the only selective tyrosine kinase inhibitor (TKI) targeting the VEGF axis that has been used to date for metastatic UC. Gallagher et al 26 used sunitinib, a TKI that inhibits VEGFR, PDGFR, KIT, FLT3, and RET, in a recent phase II study of 77

Full access

Hillary Johnson-Jahangir, William Sherman and Désirée Ratner

targeted therapy using imatinib, a selective tyrosine kinase inhibitor (TKI) with efficacy against the tyrosine kinase receptors PDGFR, KIT, and Abl/Bcr-Abl. 20 First approved by the FDA in 2001 for chronic myelogenous leukemia (CML), imatinib's approved

Full access

Keith D. Eaton and Renato G. Martins

rate of subsequent EGFR tyrosine kinase inhibitor (TKI) use in the placebo arm (16%). Because EFGR TKIs have known therapeutic benefit, the lack of crossover in this trial reinforces the data showing that erlotinib is an effective agent in NSCLC, but

Full access

Jarred Burkart, Dwight Owen, Manisha H. Shah, Sherif R. Z. Abdel-Misih, Sameek Roychowdhury, Robert Wesolowski, Sigurdis Haraldsdottir, Julie W. Reeser, Eric Samorodnitsky, Amy Smith and Bhavana Konda

twice daily) and the vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) pazopanib (600 mg orally daily) in patients with BRAF -mutated advanced malignant tumors. He received 1 month of treatment before developing acute

Full access

Darren Sigal, Marie Tartar, Marin Xavier, Fei Bao, Patrick Foley, David Luo, Jason Christiansen, Zachary Hornby, Edna Chow Maneval and Pratik Multani

identify a NTRK translocation, but did describe a novel mTOR pathway gene alteration in DEPDC5 in 2 patients (1.9%). 16 This suggests that a larger sample size may still reveal rare NTRK translocations in PNETs. Several companies have TKIs

Full access

Presenters : Chad A. LaGrange, M. Dror Michaelson and Colleen H. Tetzlaff

. Tumor histology from the spine was identical to that from the primary renal mass. Chest CT showed minimal increase in bilateral lung nodules (2–5 mm). Options for subsequent management include active surveillance; systemic therapy with VEGFR TKI

Full access

Anderson Cancer Center, b Bristol-Myers Squibb, and c Novosys Health Background: The clinical response rate for patients with chronic myelogenous leukemia (CML) to second-generation tyrosine kinase inhibitors (2G-TKI), dasatinib and nilotinib, after

Full access

David S. Ettinger, Wallace Akerley, Hossein Borghaei, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Apar Kishor P. Ganti, Ramaswamy Govindan, Frederic W. Grannis Jr, Leora Horn, Thierry M. Jahan, Mohammad Jahanzeb, Anne Kessinger, Ritsuko Komaki, Feng-Ming (Spring) Kong, Mark G. Kris, Lee M. Krug, Inga T. Lennes, Billy W. Loo Jr, Renato Martins, Janis O’Malley, Raymond U. Osarogiagbon, Gregory A. Otterson, Jyoti D. Patel, Mary C. Pinder-Schenck, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Scott J. Swanson, Douglas E. Wood, Stephen C. Yang, Miranda Hughes and Kristina M. Gregory

seem to be prognostic of survival for patients with NSCLC, independent of therapy. 59 However, the presence of the EGFR exon 19 deletion or exon 21 L858R mutation is predictive of treatment benefit with EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy

Full access

David S. Ettinger, Dara L. Aisner, Douglas E. Wood, Wallace Akerley, Jessica Bauman, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D'Amico, Thomas J. Dilling, Michael Dobelbower, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Sandip P. Patel, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory and Miranda Hughes

– 27 Initial ALK-Directed Therapy: Alectinib is an oral tyrosine kinase inhibitor (TKI) that inhibits ALK rearrangements. 28 A phase III randomized trial (ALEX) assessed first-line therapy with alectinib versus crizotinib in 303 patients with ALK